Subcutaneous infliximab for severe ulcerative colitis
Part of Digestive system clinical trials.
This study looks at whether giving infliximab as a shot under the skin, after initial IV doses, helps people with severe ulcerative colitis. It may help doctors understand if this easier way of taking the medicine works well over a year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with severe ulcerative colitis (a type of inflammatory bowel disease).
- You received at least two or three IV infusions of infliximab to start, then switched to shots under the skin.
- Your doctors have records of your health for at least 12 months after starting the shots.
- You agree to let researchers use your medical data for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.